Le 03 novembre 2021 à 19:44:52 :
t'as des ES, mais aucun dérèglement du PTA simplement une petite suppression de testo qui revient d'elle même entre 2 et 4 semaines

aucune augmentation de la prostate etc etc

médoc anti cancer qui te fait gagner de l'espérance de vie

pas du tout hépatotoxique

Ayaoo , bon bah on attend un retour alors

d'accord le ragix

miaule

Le 03 novembre 2021 à 19:48:21 :
d'accord le ragix

miaule

Qu'est ce que j'en ai à battre en fait ???

Le 03 novembre 2021 à 19:42:33 :

Le 03 novembre 2021 à 19:41:41 :
Prendre un Sarm dont l'efficacité est douteuse alors qu'un gramme de testo / semaine = t'explose

As many of you know, RAD140 was trialed in Phase 2 in humans in 2018-2020. The initial results were reviewed by MPMD and others and were interesting in at least the high dosing of RAD140 that the trial subjects took.

Now the full results of this last human clinical trial of RAD140, which completed in 2020, were published just very recently, few weeks ago. See: https://www.sciencedirect.com/science/article/abs/pii/S1526820921002408

Full paper contains some very interesting takeaways:

The researchers conclude that 100mg daily dose has had acceptable safety profile, and warrant further clinical trials (it seems to be working against cancer);

RAD140 half-life was established at ~44.7 hours;

RAD shows variable oral absorption ranging from 6 to 71 hours, suggesting that individual responses may vary;

Main side effect reported was ALT/AST elevation (they mention that the same was observed for lower dose (9/18mg trial) Enobosarm and cite the yet unpublished Enobosarm Phase 2 trial paper; BUT

The researchers argue that the elevation of transaminases is due to “androgenic effect related to increased enzyme synthesis in hepatic and non hepatic tissues (there are androgen response elements present on the ALT and AST genes). This could explain the high frequency of elevated transaminazes in the absence of evidence of hepatic toxicity.” This basically claims that ALT/AST elevation by SARMs may be benign and does not indicate liver toxicity, also in both Enobosarm and RAD140 trials the elevation is said to be transient and normalizes after stoping the compound;

Whether it is liver toxic or not, it may be worthwhile to note that 18mg of Enobosarm may on average have the same (or higher ?) impact on the liver as 100mg of RAD140, although in current broscience Enobosarm (Ostarine) is thought to be somewhat milder on the organs (hair is another story), and because of it Osta is commonly cycled at 25mg/day (higher than in clinical trials), while RAD at 10-20mg/day (much lower than clinical trials).

I am not advocating anyone to shoot for 100mg/day RAD140 cycle, especially since we know that it has some other side effects on hair, mood, sleep, etc., but it may be rather encouraging that it does not require a liver transplant even at this high dosing.

Putain 100mg/jour
Le test a été fait chez 21 femmes ménoposées avec cancer du sein bordel tu parles d'un truc représentatif

Le 04 novembre 2021 à 00:55:55 :

Le 03 novembre 2021 à 19:42:33 :

Le 03 novembre 2021 à 19:41:41 :
Prendre un Sarm dont l'efficacité est douteuse alors qu'un gramme de testo / semaine = t'explose

As many of you know, RAD140 was trialed in Phase 2 in humans in 2018-2020. The initial results were reviewed by MPMD and others and were interesting in at least the high dosing of RAD140 that the trial subjects took.

Now the full results of this last human clinical trial of RAD140, which completed in 2020, were published just very recently, few weeks ago. See: https://www.sciencedirect.com/science/article/abs/pii/S1526820921002408

Full paper contains some very interesting takeaways:

The researchers conclude that 100mg daily dose has had acceptable safety profile, and warrant further clinical trials (it seems to be working against cancer);

RAD140 half-life was established at ~44.7 hours;

RAD shows variable oral absorption ranging from 6 to 71 hours, suggesting that individual responses may vary;

Main side effect reported was ALT/AST elevation (they mention that the same was observed for lower dose (9/18mg trial) Enobosarm and cite the yet unpublished Enobosarm Phase 2 trial paper; BUT

The researchers argue that the elevation of transaminases is due to “androgenic effect related to increased enzyme synthesis in hepatic and non hepatic tissues (there are androgen response elements present on the ALT and AST genes). This could explain the high frequency of elevated transaminazes in the absence of evidence of hepatic toxicity.” This basically claims that ALT/AST elevation by SARMs may be benign and does not indicate liver toxicity, also in both Enobosarm and RAD140 trials the elevation is said to be transient and normalizes after stoping the compound;

Whether it is liver toxic or not, it may be worthwhile to note that 18mg of Enobosarm may on average have the same (or higher ?) impact on the liver as 100mg of RAD140, although in current broscience Enobosarm (Ostarine) is thought to be somewhat milder on the organs (hair is another story), and because of it Osta is commonly cycled at 25mg/day (higher than in clinical trials), while RAD at 10-20mg/day (much lower than clinical trials).

I am not advocating anyone to shoot for 100mg/day RAD140 cycle, especially since we know that it has some other side effects on hair, mood, sleep, etc., but it may be rather encouraging that it does not require a liver transplant even at this high dosing.

Putain 100mg/jour
Le test a été fait chez 21 femmes ménoposées avec cancer du sein bordel tu parles d'un truc représentatif

T'inquiète il gère

bonne chance khey hate de voir l'avant apres

Rad-140 c'est ligandrol ?

Non ligandrol c'est le Lgd 4033

C'est pas le truc qui nique ta vision ? Genre tu vois jaune carrément